A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Congenital Hyperinsulinism

Interventions

DRUG

Cohort 1

XOMA 358 single dose level A administered by an intravenous infusion

DRUG

Cohort 2

XOMA 358 single dose level B administered by an intravenous infusion

DRUG

Cohort 3

XOMA 358 single dose level C administered by an intravenous infusion

DRUG

Cohort 4

XOMA 358 single dose level D administered by an intravenous infusion

Trial Locations (2)

Philadelphia

London

All Listed Sponsors

lead

XOMA (US) LLC

INDUSTRY

NCT02604485 - A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism | Biotech Hunter | Biotech Hunter